background preloader

Papillo

Facebook Twitter

Greif- und Anziehhilfen. AFH-Webshop - Therapie und Praxis Bedarf zu günstigen Preisen. The Niche - Knoepfler lab stem cell blog. Fraud Alert! Unproven Stem Cell Use Prompts International Call to Action. Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism” Clarifying Stem-Cell Therapy’s Benefits and Risks. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. Macchiarini’s trachea transplant patients: the full list – For Better Science. This article lists all known (including those not officially declared) patients of the scandal surgeon Paolo Macchiarini, who received from him a cadaveric or plastic trachea.

Macchiarini’s trachea transplant patients: the full list – For Better Science

All these grafts were “regenerated” with bone marrow and epithelial cells, in some cases a bioreactor was used to incubate cells on the trachea carcass, in some cases a “bionic” method was applied, where cells were brought straight into the open patient, together with growth factors like EPO. Not all patients are named in my list, though names of all are available, certainly at the hospitals where they were treated. One of my sources is a patients list from the Careggi Hospital in Florence, Italy, which the Corriere Fiorentino journalist Alessio Gaggioli sent me.

Some of the patients I already described in an earlier article. This now is a full list, and it will be updated whenever I receive any new evidence. Claudia Castillo, born 1977, suffered from tuberculosis-damaged airways. 17. 18. +19. Update 3.10.2017. Unproven Stem Cell Treatments Offer Hope & Risks. The injections of stem cells into his spine were supposed to help Jim Gass, 66, recover from a stroke he had six years ago.

Unproven Stem Cell Treatments Offer Hope & Risks

Gass traveled to clinics in Mexico, China, and Argentina to undergo these unproven procedures. Including travel, he spent close to $300,000, according to a story in The New York Times. After the final round of shots, he was able to walk better. But his hope for a full recovery was cut short. While on vacation in Thailand six months after his treatments, he developed low back pain and difficulty walking and standing. Back in Boston, doctors at Brigham and Women’s Hospital did an MRI scan of his spine, and found a large mass filling the entire lower part of his spinal column. Genetic testing revealed that the abnormal, primitive cells of the mass did not come from Gass, but from stem cells injected into his spine. Radiation treatments seemed to slow the growth of the mass and improve Gass’ symptoms. Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”

Are Trials of Intravascular Infusions of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy Currently Justified, and Are They Effective? - Quinn - 2008 - Clinical Pharmacology & Therapeutics - Wiley Online Library. Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. JavaScript is disabled on your browser.

Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain

Please enable JavaScript to use all the features on this page. Highlights Current clinical status of cell based therapies for neurodegenerative disorders. The ethical concerns with using and studying different types of stem cells. The ethical issues with stem cells in treating patients with cognitive deficits. The ethical problems of experimental cell based trials for brain diseases.

Abstract. Towards Clinical Application of Mesenchymal Stem Cells for Treatment of Neurological Diseases of the Central Nervous System. Optimization of Pre-transplantation Conditions to Enhance the Efficacy of Mesenchymal Stem Cells. Novel therapeutic approaches in multiple system atrophy. Review Article First Online: Received: Accepted: Abstract.

Novel therapeutic approaches in multiple system atrophy

Review: Multiple system atrophy: emerging targets for interventional therapies - Stefanova - 2016 - Neuropathology and Applied Neurobiology. Multiple system atrophy: insights into a rare and debilitating movement disorder. Are Trials of Intravascular Infusions of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy Currently Justified, and Are They Effective? - Quinn - 2008 - Clinical Pharmacology & Therapeutics - Wiley Online Library. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? - Low - 2012 - Annals of Neurology. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? - Low - 2012 - Annals of Neurology. Towards translational therapies for multiple system atrophy. JavaScript is disabled on your browser.

Towards translational therapies for multiple system atrophy

Please enable JavaScript to use all the features on this page. Open Access funded by Austrian Science Fund (FWF) open access Highlights This review summarizes the progress made in MSA research during the past decade. Pre-motor features have gained relevance as early diagnostic markers. Animal models have been exploited to discover novel interventional targets. Towards translational therapies for multiple system atrophy. JavaScript is disabled on your browser.

Towards translational therapies for multiple system atrophy

Please enable JavaScript to use all the features on this page. Mesenchymal stem cell-derived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders. Mesenchymal stem cell-derived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders. Mesenchymal stem cell transplantation in multiple sclerosis - Journal of the Neurological Sciences. An update on the cerebellar subtype of multiple system atrophy. 2.1 Pathology Twenty years ago Papp and coworkers identified, for the first time, the argyrophilic filamentous aggregates localized in the cytoplasm of oligodendrocytes that were common to all MSA variants.

An update on the cerebellar subtype of multiple system atrophy

These inclusion bodies were subsequently termed glial cytoplasmic inclusions (GCIs) or Papp-Lantos bodies [10]. GCIs are typically associated with gliosis and neuronal loss in the basal ganglia, cerebellum, pons, inferior olivary nucleus, and spinal cord. A randomized trial of mesenchymal stem cells in multiple system atrophy - Lee - 2012 - Annals of Neurology. Los expertos advierten por tratamientos experimentales de células madre. (Reuters) - Existe un gran potencial en el campo de la medicina regenerativa, pero los médicos advierten sobre buscar tratamientos experimentales en un entorno sin regulación.

Los expertos advierten por tratamientos experimentales de células madre

Después de pasar por tres cirugías debido a una lesión en el cuello, se informó que el mariscal de campo de los Potros de Indianápolis, Peyton Manning, tomó un avión privado hacia Europa para recibir un tratamiento de células madre que no está aprobado en Estados Unidos. La terapia incluye inyecciones de células de grasa del cuerpo de Manning en su cuello, de acuerdo con Fox Sports. La opción de viajar para recibir tratamientos experimentales con células madre pone a los investigadores en una posición incómoda, porque las terapias que se ofrecen no están reguladas y no está confirmado que funcionen, aunque la comunidad médica cree que tienen potencial. La idea básica es que las células madre tienen un potencial regenerativo, y que incluso pueden formar nuevos tejidos.

El peligro de las terapias de células madre no aprobadas por Salud Canadá. Un médico en una clínica de células madre en Beverly Hills, California, recolecta grasa de la espalda de un paciente como parte de un procedimiento de células madre en 2014.

El peligro de las terapias de células madre no aprobadas por Salud Canadá

Estados Unidos ha experimentado un auge en clínicas con fines de lucro que comercializan células madre para pacientes en un amplio rango de dolencias Los críticos dicen que han florecido debido a la falta de supervisión. Tratamientos riesgosos con células madre se expanden por EE.UU. Nytimes. Jorge Tuma - Team. Integrated by outstanding specialists from our country that combine a vast medical experience with a permanent reasearch work on the regenerative therapy area.

Jorge Tuma - Team

Each member has been selected by his proven academic trajectory, his human quality and wide experience in the application of stem cells by therapeutic interventionism. JORGE TUMA MUBARAK, MD (Curriculum Vitae) "Stem Cell Tourists" Go Abroad for Unproven Treatments. December 3, 2008 When Robert Ramirez was diagnosed with Parkinson's disease in 2006, his doctor gave him medication, but little hope: "He told me there wasn't much I could do except wait to 'pass to the other side.'" Ramirez, a Peruvian-American mechanic in northern New Jersey, watched helplessly as his symptoms worsened.

His left arm grew weak. His leg muscles went rigid. His trembling intensified. GetSharedSiteSession?rc=4&redirect= Introduction Multiple system atrophy (MSA) is a rare but distinctive and fatal α-synucleinopathy characterised by autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal signs in various combinations. These symptoms are the result of overlapping pathologies including striatonigral, olivopontocerebellar, and central autonomic degeneration.1, 2 Two phenotypes can be distinguished clinically by the predominant motor symptom: the parkinsonian variant (MSA-P) and the cerebellar variant (MSA-C).3 However, autonomic features can predate motor impairment.4, 5 Premotor MSA is increasingly recognised as a cluster of symptoms including not only progressive autonomic failure, but also sleep disorders such as rapid eye movement sleep behaviour disorder, central sleep apnoea, and stridor.6 Methods.

Models of Multiple System Atrophy. An update on the cerebellar subtype of multiple system atrophy. Atrofia multisistémica. Atrofia multisistémica - Enfermedades cerebrales, medulares y nerviosas - Manual MSD versión para público general. La atrofia multisistémica es un trastorno progresivo y mortal que provoca la rigidez de los músculos con los consiguientes problemas de movimiento, pérdida de coordinación y disfunción de los procesos internos del organismo (como la presión arterial y el control de la vejiga).

EMSA-SG: European Multiple System Atrophy Study Group > Qué es la MSA. Therapeutic strategies in multiple system atrophy - Wenning - 2005 - Movement Disorders. This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord.

Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open-label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate-to-good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. An update on the cerebellar subtype of multiple system atrophy. Low HDL Cholesterol (Hypoalphalipoproteinemia) Treatment & Management: Medical Care, Surgical Care, Consultations. The document also reported that there are several causes of low HDL cholesterol levels and that a number of these—including type II diabetes, overweight, obesity, elevated triglycerides (TGs), and a lack of physical activity—are associated with insulin resistance. The study also cited cigarette smoking, a very high carbohydrate intake (>60% of calories), and certain agents (such as progestational drugs, anabolic steroids, and beta blockers) as causes of low HDL levels.

Follow an appropriate management strategy. The ATP III report did not provide a specific level to which a low HDL concentration should be raised. According to the study's executive summary, "Although clinical trial results suggest that raising HDL will reduce risk, the evidence is insufficient to specify a goal of therapy. Furthermore, currently available drugs do not robustly raise HDL cholesterol. " Confirmation.html?aid=304142;label=gen173nr-1FCAEoggJCAlhYSDNiBW5vcmVmaDuIAQGYATHCAQp3aW5kb3dzIDEwyAEM2AEB6AEB-AECkgIBeagCAw;sid=1003379c21053feb8d4cdd84a29b9e0d;auth_key=uqwYKHpPjPnIJlDU;hostname=www.booking.

National Ataxia Foundation - Depression & Ataxia. Many people believe that living a good life is an entirely reasonable aspiration even with ataxia. However, for some, ataxia can cause mental and psychological anguish that comes with unanswered questions, stares of curious people, the fear of choking, and the progression of the disease. Clinica San Antonio. Degeneración cerebelosa : National Institute of Neurological Disorders and Stroke (NINDS) UKB Universitätsklinikum BONN / Medizinische Fakultät - Neurology. <br/> „Our Department of Neurology offers a complete clinical treatment for all neurologic diseases. The clinical and scientific focus is on neurodegenerative diseases, brain tumors, muscle disorders, cerebrovascular diseases and multiple sclerosis. After an accurate neurologic examination, it’s very often possible to locate brain or spinal disturbances.

In other diseases, e.g. Parkinson’s disease merely the medical history and clinical examinations may lead to an accurate diagnosis. Cerebellar DIsorders. Timothy C. Hain, MD Page last modified: January 11, 2017 This page is meant to provide a general outline of cerebellar disorders. More specific and detailed material is found in links. What is the cerebellum and what does it do ? The cerebellum is part of the brain. Olivopontocerebellar Atrophy Clinical Presentation: History, Physical, Causes. Friedreich N. Ueber degenerative atrophie der spinalen Hinterstrange. Virchow Arch Path Anat. 1863. 26:391-419. Friedreich N. Ueber degenerative atrophie der spinalen Hinterstrange.